NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Core Points - NanoViricides, Inc. has entered into a securities purchase agreement with a healthcare institutional investor for the sale of 3,571,429 shares of common stock at a price of $1.68 per share [1] - The gross proceeds from this registered direct offering are expected to be approximately $6 million, before deducting placement agent commissions and other offering expenses [1] Company Summary - The offering involves the sale of common stock or common stock equivalents [1] - The transaction is structured as a registered direct offering, indicating a streamlined process for raising capital [1]